Topic · Research

Peptide Research News by Country

Studies and trials run in or for one market. 1 story from 1 countries.

AP1

Desk

Stories

1 story

KRSouth KoreaResearch26 Oct 2026

Daewon oral semaglutide tablet DW5324 beats Rybelsus exposure in two small studies

Daewon Pharmaceutical says its oral semaglutide candidate DW5324 reached 1.90 to 3.14 times the exposure of Rybelsus in two crossover studies of 18 and 19 people, presented at AAPS PharmSci 360.

About this topic

The Research topic collects studies and trials that matter to one market: a local trial that a regulator will rely on, a new formulation such as an oral tablet developed by a regional company, or a study of how a medicine is used in one health system. Stories say what kind of study it was, how many people or samples it included, who ran and paid for it, and what it cannot show. Early results from small studies are labelled as early. We report research as news about a market and its companies, not as advice, and we never turn a study amount into a dose for anyone to follow. Readers who want the science itself in depth will find it in the cited papers listed under each story. Like every topic, research stories are filed by country and can be filtered by desk.